Skip to content
Head to head

Nurix Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: NRIX · VRTX

Updated 7 minutes ago

1-year performance, rebased to 100

NRIX +0.5%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
NRIXVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price12.85515.02
Change today-5.51%-1.08%
1-year return-16.2%+22.0%
Market cap$1.40B$130.58B
52-week range12.83 – 28.23412.27 – 568.67
Valuation
P/E (TTM)5.2933.14
P/E percentile, own 5-yr range98th99th
P/B1.456.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-3.0515.32
Net profit (TTM)$-333.21M$3.88B
Revenue (TTM)$701.94M$12.95B
Provider revenue period date2026-08-302026-09-29
Revenue growth (YoY)+8426.3%+11.8%
Gross margin--85.5%
Operating margin41.3%33.1%
Net margin42.0%30.7%
Free cash flow (TTM)$369.81M$3.20B
Provider cash-flow period date2026-08-302026-09-29
Ownership & sentiment
Institutional ownership108.9%96.8%
Insider activity (12mo)17 buy / 33 sell28 buy / 22 sell
Short interest (% of float)17.3%1.9%
Analyst consensus100% buy (9)95% buy / 5% hold (21)
Analyst price target$35 (+175%)$624 (+21%)
StockVane view
StockVane Quant RatingD (28)C (68)
Company
Employees3176,400
Founded20091989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.